Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP-Reference-Cited by-同舟云学术

Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP

Published:2005-02 Issue:2 Volume:1033 Page:216-220
ISSN:0006-8993
Container-title:Brain Research
language:en
Short-container-title:Brain Research

Author:

Aguirre Jose A.,Kehr Jan,Yoshitake Takashi,Liu Fang-Ling,Rivera Alicia,Fernandez-Espinola Sergio,Andbjer Beth,Leo Giuseppina,Medhurst Andrew D.,Agnati Luigi F.,Fuxe Kjell

Publisher

Elsevier BV

Subject

Developmental Biology,Clinical Neurology,Molecular Biology,General Neuroscience

Reference9 articles.

1. Computer-assisted morphometry and microdensitometry of transmitter-identified neurons with special reference to the mesostriatal dopamine pathway. Methodological aspects;Agnati;Acta Physiol. Scand., Suppl.,1984

2. Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury;Aguirre;NeuroReport,2001

3. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice;Battaglia;J. Neurosci.,2004

4. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity;Battaglia;J. Neurosci.,2002

5. Changes in dialysate concentrations of glutamate and GABA in the brain: an index of volume transmission mediated actions?;Del Arco;J. Neurochem.,2003

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease;Cells;2023-03-24

2. In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease;Current Neuropharmacology;2018-06-08

3. Downregulation of metabotropic glutamate receptor 5 inhibits hepatoma development in a neurotoxin rotenone-induced Parkinson’s disease model;Toxicology Letters;2018-05

4. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia;Current Opinion in Pharmacology;2018-02

5. Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson’s disease on liver cancer;Pharmacological Research;2017-07